Open menu Close menu Open Search Close search

AMERICAN DRUGS | ANATOMY | HEALTH TOPICS | HIV/AIDS GLOSSARY | DISEASES | HEALTH ARTICLES | GENOME | OCCUPATIONS

Leucogen

Spanish Simplified Chinese French German Russian Hindi Arabic Portuguese















Summary for the public


What is Leucogen?

Leucogen is a vaccine for cats that contains a protein of feline leukaemia virus (FeLV).

Leucogen is available as a suspension for injection.


What is Leucogen used for?

Leucogen is used to vaccinate cats from eight weeks of age against feline leukaemia (an illness affecting the immune system caused by a retrovirus). It is used to prevent the symptoms of the disease and to prevent FeLV from remaining in the blood.

Leucogen is given to kittens as two injections under the skin. The first injection is given when the kitten is about eight weeks old, and the second three/four weeks later. Afterwards, cats need a booster injection every year.


How does Leucogen work?

Leucogen is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. Leucogen contains small amounts of a protein from the FeLV called ‘envelope p45 protein’. The FeLV protein used in the vaccine is not extracted from viruses but is made in a bacterium using ‘recombinant DNA technology’.

When a cat is given the vaccine, the immune system recognises the FeLV protein as ‘foreign’ and makes antibodies against it. In the future, the immune system will be able to produce antibodies more quickly when it is exposed to FeLV. The antibodies will help to protect against the disease caused by the virus. When exposed to the virus later in life, the cat will either not become infected or have a much less serious infection.


How has Leucogen been studied?

Because Leucogen has been available in the European Union (EU) since 1988, and is also used as part of a multivalent vaccine called Leucofeligen FeLV/RCP, the company used data from studies carried out with these vaccines to support the use of Leucogen.

Two main ‘field’ studies involved kittens aged eight to nine weeks, the first using Leucogen and the second using Leucofeligen FeLV/RCP. The main measure of effectiveness was the presence of antibodies against FeLV in the vaccinated kittens’ blood. Further studies were carried out under laboratory conditions to show that vaccination prevented FeLV from remaining in the blood.


What benefit has Leucogen shown during the studies?

The studies showed that Leucogen provided protection against FeLV infection. Vaccination on two occasions with three to four weeks between injections prevented FeLV from remaining in the blood and prevented the signs of FeLV infection.


What is the risk associated with Leucogen?

A temporary small nodule (hard swelling) may appear at the site of injection. This usually resolves on its own within three to four weeks. This reaction is reduced after subsequent injections. In rare cases, there may be pain on being touched, sneezing or conjunctivitis (eye inflammation). These resolve without any treatment. The temporary usual signs following vaccination, such as increased temperature, apathy (listlessness) and digestive problems such as abdominal discomfort may also be seen following vaccination. For a full list of all side effects reported with Leucogen, see the Package Leaflet. Leucogen should not be used in pregnant cats. Its use is not recommended in cats nursing kittens.


What are the precautions for the person who gives the medicine or comes into contact with the animal?

In case of accidental self-injection, seek medical advice immediately and show the Package Leaflet or the label to the doctor.


Why has Leucogen been approved?

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Leucogen exceed the risks for the active immunisation of cats from eight weeks of age against feline leukaemia, and recommended that Leucogen be given a marketing authorisation. The benefit-risk balance may be found in module 6 of this EPAR.


Other information about Leucogen

The European Commission granted a marketing authorisation valid throughout the EU for Leucogen to Virbac S.A. on 17 June 2009. Information on the prescription status of this product may be found on the label/outer package.

Authorisation details
Name: Leucogen
EMEA Product number: EMEA/V/C/000144
Active substance: purified p45 FeLV-envelope antigen
INN or common name: Adjuvanted vaccine against feline leukaemia
Species: Cats
ATCvet Code: QI06AA01
Marketing Authorisation Holder: Virbac S.A.
Revision: 0
Date of issue of Market Authorisation valid throughout the European Union: 17/06/2009
Contact address:
Virbac S.A.
1ère Avenue 2065 M
06516 Carros
France



  • Drugs Alphabetically





    • Product Characteristics

    ANNEX I

    SUMMARY OF PRODUCT CHARACTERISTICS


    1.
    NAME OF VETERINARY THE MEDICINAL PRODUCT
    LEUCOGEN suspension for injection for cats.
    2.
    QUALITATIVE AND QUANTITATIVE COMPOSITION
    Per dose of 1 ml:
    Minimum quantity of purified p45 FeLV-envelope antigen
    102 µg
    3 % aluminium hydroxide gel expressed as mg Al
    1 mg
    Purified extract of Quillaja saponaria
    10 µg
    Excipients:
    Buffered isotonic solution to
    1 ml
    For a full list of excipients, see section 6.1
    3.
    PHARMACEUTICAL FORM
    Suspension for injection.
    Opalescent liquid.
    4.
    CLINICAL PARTICULARS
    4.1 Target species
    Cats
    4.2 Indications for use, specifying the target species
    Active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of
    persistent viraemia and clinical signs of the related disease.
    Onset of immunity: 3 weeks after the primary vaccination.
    The duration of immunity is one year after the primary vaccination .
    4.3 Contraindications
    None.
    4.4 Special warnings
    None.
    2
    Active substance:
    Adjuvants:
    4.5 Special precautions for use
    Special precautions for use in animals
    - Vaccinate only healthy animals.
    - De-worming at least 10 days prior to vaccination is recommended.
    - Only Feline Leukaemia Virus (FeLV) negative cats should be vaccinated. Therefore, a test for
    presence of FeLV before vaccination is recommended.
    Special precautions to be taken by the person administering the veterinary medicinal product to
    animals
    In case of accidental self-injection, seek medical advice immediately and show the package leaflet or
    the label to the physician.
    4.6 Adverse reactions (frequency and seriousness)
    After the first injection, a moderate and transient local reaction ( < 2 cm) can occur (oedema, swelling,
    nodule). This reaction resolves spontaneously within 3 to 4 weeks at the most. After the second
    injection, and subsequent administrations, this reaction is markedly reduced. In rare cases, pain at
    palpation, sneezing or conjunctivitis may be noted, that resolves without any treatment. The transient
    usual signs following vaccination may also be observed, such as: hyperthermia (lasting 1 to 4 days),
    apathy, digestive disturbances.
    In case of anaphylactic shock, appropriate symptomatic treatment should be administered.
    4.7 Use during pregnancy, lactation or lay
    Do not use in pregnant cats.
    Use is not recommended during lactation.
    4.8 Interaction with other medicinal products and other forms of interaction
    Safety and efficacy data are available which demonstrate that this vaccine can be mixed with
    FELIGEN CRP or FELIGEN RCP.
    4.9 Amounts to be administered and administration route
    Subcutaneous use.
    Shake gently the vial and administer subcutaneously one dose of the veterinary medicinal product
    according to the following regimen of vaccination.
    Primary vaccination:
    - first injection in kittens from eight weeks of age
    - second injection 3 or 4 weeks later.
    Maternally derived antibodies can negatively influence the immune response to vaccination. In such
    cases where maternally derived antibodies are expected, a third injection may be appropriate from 15
    weeks of age.
    Revaccination:
    Annual
    3
    4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
    No adverse reactions were observed after an overdose administration (2 doses) of the veterinary
    medicinal product other than those mentioned in section 4.6 except local reactions that can last longer
    (5 to 6 weeks at the most).
    4.11 Withdrawalperiod
    Not applicable.
    5.
    IMMUNOLOGICAL PROPERTIES
    Pharmacotherapeutic group: Inactivated viral vaccine
    ATCvetcode: QI06AA01
    Vaccine against feline leukaemia.
    The vaccine contains the purified p45 FeLV-envelope antigen, obtained by genetic recombination of
    the E. Coli strain. The antigenic suspension is adjuvanted with an aluminium hydroxide gel and with a
    purified extract of Quillaja Saponaria.
    6.
    PHARMACEUTICAL PARTICULARS
    6.1 List of excipients
    Sodium chloride
    Disodium phosphate anhydrous
    Potassium dihydrogen phosphate
    Aluminium hydroxide
    Quillaja saponaria
    6.2 Incompatibilities
    Do not mix with any other vaccine or immunological product except FELIGEN RCP or FELIGEN
    CRP.
    6.3 Shelf life
    Shelf life of the veterinary medicinal product as packaged for sale: 2 years
    Shelf-life after first opening the immediate packaging: use immediately
    6.4. Specialprecautionsforstorage
    Store and transport refrigerated (2
    °
    C – 8
    °
    C)
    Do not freeze
    Protect from light
    4
    6.5 Nature and composition of immediate packaging
    A 3 ml-glass vial with a 13 mm-diameter butyl elastomer stopper and set with an aluminium capsule.
    Box of 10 vials
    Box of 50 vials
    Not all pack sizes may be marketed.
    6.6 Special precautions for the disposal of unused veterinary medicinal product or waste
    materials derived from the use of such products
    Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal
    products should be disposed of in accordance with local requirements.
    7.
    MARKETING AUTHORISATION HOLDER
    Virbac
    1ère avenue – 2065 m – L.I.D.
    06516 Carros Cedex
    France
    8.
    MARKETING AUTHORISATION NUMBER(S)
    EU/2/09/096/001
    EU/2/09/096/002
    9.
    DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
    17/06/2009
    10 DATE OF REVISION OF THE TEXT
    17/06/2009
    Detailed information on this veterinary medicinal product is available on the website of the European
    Medicines Agency (EMEA) http://www.emea.europa.eu /.
    PROHIBITION OF SALE, SUPPLY AND/OR USE
    Not applicable.
    5
    ANNEX II
    A.
    MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND
    MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR
    BATCH RELEASE
    B.
    CONDITIONS OR RESTRICTIONS OF THE MARKETING
    AUTHORISATION REGARDING SUPPLY OR USE
    C.
    CONDITIONS OR RESTRICTIONS OF THE MARKETING
    AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
    D.
    STATEMENT OF THE MRLs
    6
    A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND
    MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH
    RELEASE
    Name and address of the manufacturer(s) of the biological active substance(s)
    PP MANUFACTURING CORPORATION
    175 crossing Boulevard, Suite 200, Framingham, Massachusetts 01702, USA
    Name and address of the manufacturer(s) responsible for batch release
    Virbac
    1ère avenue – 2065 m – L.I.D., 06516 Carros Cedex France
    B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION
    REGARDING SUPPLY OR USE
    To be supplied only on veterinary prescription.
    C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH
    REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
    Not applicable.
    D. STATEMENT OF THE MRLs
    Not applicable.
    7
    ANNEX III
    LABELLING AND PACKAGE LEAFLET
    8
    A. LABELLING
    9
    PARTICULARS TO APPEAR ON THE OUTER PACKAGE
    Box of 10 vials
    Box of 50 vials
    1.
    NAME OF VETERINARY THE MEDICINAL PRODUCT
    LEUCOGEN suspension for injection for cats.
    2.
    STATEMENT OF ACTIVE AND OTHER SUBSTANCES
    Per dose of 1 ml:
    Active substance:
    Minimum quantity of purified p45 FeLV-envelope antigen: 102 µg
    Adjuvants:
    3 % aluminium hydroxide gel, Purified extract of Quillaja saponaria
    Excipients:
    Buffered isotonic solution
    3.
    PHARMACEUTICAL FORM
    Suspension for injection .
    4.
    PACKAGE SIZE
    Box of 10 vials
    Box of 50 vials.
    5.
    TARGET SPECIES
    Cats
    6.
    INDICATION(S)
    Active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of
    persistent viraemia and clinical signs of the related disease.
    Onset of immunity: 3 weeks after the primary vaccination.
    The duration of immunity is one year after the primary vaccination .
    7.
    METHOD AND ROUTE(S) OF ADMINISTRATION
    Subcutaneous use
    10
     
    8.
    WITHDRAWAL PERIOD
    Not applicable
    9.
    SPECIAL WARNING(S), IF NECESSARY
    Read the package leaflet before use
    10. EXPIRY DATE
    EXP {month/year}
    Once broached the product should be used immediately.
    11. SPECIAL STORAGE CONDITIONS
    Store and transport refrigerated (2
    °
    C – 8
    °
    C)
    Do not freeze
    Protect from light
    12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
    WASTE MATERIALS, IF ANY
    Disposal: read the package leaflet
    13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR
    RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
    For animal treatment only - to be supplied only on veterinary prescription
    14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
    Keep out of the reach and sight of children.
    15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
    Virbac, 1ère avenue – 2065 m – L.I.D., 06516 Carros Cedex France
    16. MARKETING AUTHORISATION NUMBER(S)
    EU/2/09/096/001
    EU/2/09/096/002
    11
     
    17. MANUFACTURER’S BATCH NUMBER
    Lot {number}
    12
     
    MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
    Vial label
    1.
    NAME OF VETERINARY THE MEDICINAL PRODUCT
    LEUCOGEN suspension for injection for cats
    2.
    QUANTITY OF THE ACTIVE SUBSTANCE(S)
    Minimum quantity of purified p45 FeLV-envelope antigen, 102 µg
    3.
    CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
    1 dose of 1 ml
    4.
    ROUTE(S) OF ADMINISTRATION
    Subcutaneous use
    5.
    WITHDRAWAL PERIOD
    Not applicable
    6.
    BATCH NUMBER
    Lot {number}
    7.
    EXPIRY DATE
    EXP {month/year}>
    Once broached the product should be used immediately.
    8.
    THE WORDS “FOR ANIMAL TREATMENT ONLY”
    For animal treatment only.
    13
     
    B. PACKAGE LEAFLET
    14
    PACKAGE LEAFLET FOR:
    LEUCOGEN Suspension for injection for cats
    1.
    NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
    THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
    RELEASE, IF DIFFERENT
    Marketing authorisation holder and manufacturer for the batch release:
    Virbac, 1 ère avenue – 2065 m – L.I.D., 06516 Carros Cedex France
    2.
    NAME OF VETERINARY THE MEDICINAL PRODUCT
    LEUCOGEN suspension for injection for cats
    3.
    STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
    Per dose of 1 ml:
    Active substance:
    Minimum quantity of purified p45 FeLV-envelope antigen: 102 µg
    Adjuvants:
    3 % aluminium hydroxide gel expressed as mg Al :1 mg
    Purified extract of Quillaja saponaria : 10 µg
    Excipients:
    Buffered isotonic solution to 1 ml
    Opalescent liquid.
    4.
    INDICATION(S)
    Active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of
    persistent viraemia and clinical signs of the related disease.
    Onset of immunity: 3 weeks after the primary vaccination.
    The duration of immunity is one year after the primary vaccination .
    5.
    CONTRAINDICATIONS
    None
    6.
    ADVERSE REACTIONS
    After the first injection, a moderate and transient local reaction ( < 2 cm) can occur (oedema, swelling,
    nodule). This reaction resolves spontaneously within 3 to 4 weeks at the most. After the second
    injection, and subsequent administrations, this reaction is markedly reduced. In rare cases, pain at
    palpation, sneezing or conjunctivitis (eye inflammation) may be noted, that resolves without any
    treatment. The transient usual signs following vaccination may also be observed: hyperthermia
    (lasting1 to 4 days), apathy (listlessness), digestive disturbances (abdominal discomfort).
    In case of anaphylactic shock, appropriate symptomatic treatment should be administered.
    15
    If you notice any serious effects or other effects not mentioned in this leaflet, please inform your
    veterinary surgeon.
    7.
    TARGET SPECIES
    Cats
    8.
    DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
    Subcutaneous use (under the skin).
    Administer subcutaneously (under the skin) one dose of the veterinary medicinal product according to
    the following regimen of vaccination.
    Primary vaccination:
    - first injection in kittens from eight weeks of age
    - second injection 3 or 4 weeks later.
    Maternally derived antibodies can negatively influence the immune response to vaccination. In such
    cases where maternally derived antibodies are expected, a third injection may be appropriate from 15
    weeks of age.
    Revaccination: Annual
    9.
    ADVICE ON CORRECT ADMINISTRATION
    Shake gently the vial before use.
    10. WITHDRAWAL PERIOD
    Not applicable.
    11. SPECIAL STORAGE PRECAUTIONS
    Keep out of the reach and sight of children.
    Store and transport refrigerated (2
    °
    C – 8
    °
    C).
    Do not freeze.
    Protect from light.
    Do not use after the expiry date stated on the label after EXP{ month/year }
    Once broached, the product should be use immediately.
    12. SPECIAL WARNING(S)
    Interactions with other medicinal products
    Safety and efficacy data are available which demonstrate that this vaccine can be mixed with FELIGEN
    CRP and FELIGEN RCP.
    16
    Overdose
    No adverse reactions were observed after an overdose administration of the veterinary medicinal
    product other than those mentioned in section 6, except local reactions that can last longer (5 to 6
    weeks at the most
    Special precautions for use in animals
    Vaccinate only healthy animals.
    De-worming at least 10 days prior to vaccination is recommended.
    Only FeLV negative cats should be vaccinated. Therefore, a test for presence of FeLV before
    vaccination is recommended.
    In case of anaphylactic shock, appropriate symptomatic treatment should be administered
    Special precautions for the person administering the product
    In case of accidental self-injection, seek medical advice immediately and show the package leaflet or
    the label to the physician.
    Use during pregnancy, lactation or lay
    Do not use in pregnant cats. Use is not recommended during lactation
    13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE
    MATERIALS, IF ANY
    Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon
    how to dispose of medicines no longer required. These measures should help to protect the environment.
    14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
    17/06/2009
    Detailed information on this product is available on the website of the European Medicines Agency
    (EMEA) http://www.emea.europa.eu
    15. OTHER INFORMATION
    Immediate packaging:
    A 3 ml-glass vial with a 13 mm-diameter butyl elastomer stopper and set with an aluminium capsule.
    Box of 10 vials
    Box of 50 vials
    Not all pack sizes may be marketed
    For any information about this veterinary medicinal product, please contact the local representative of
    the marketing authorisation holder.
    België/Belgique/Belgien
    VIRBAC BELGIUM S.A.
    Rue de la station 17
    B-1300 WAVRE
    Tel: 32 (0) 10 47 06 35
    Luxembourg/Luxemburg
    VIRBAC BELGIUM S.A.
    Rue de la station 17
    B-1300 WAVRE
    Tel: 32 (0) 10 47 06 35
    17
    Република България
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Magyarország
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Česká republika
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Malta
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Danmark
    VIRBAC Danmark A/S
    Profilvej 1
    6000 Kolding
    Tel: 45 2219 1733
    Nederland
    VIRBAC NEDERLAND BV
    Hermesweg 15
    NL-3771 ND-Barneveld
    Tel: 31 (0) 342 427 100
    Eesti
    OÜ ZOOVETVARU
    Pärnasalu 31
    ET -76505 Saue/Harjumaa, ESTONIA
    Tel: + 372 6 709 006
    E-mail: margus@zoovet.ee
    Österreich
    VIRBAC Österreich GmbH
    Hildebrandgasse 27
    A-1180 Wien
    Tel: 43 (0) 1 21 834 260
    Ελλάδα
    VIRBAC HELLAS A.E.
    23 rd Klm National Road Athens-Lamia
    145 65 Agios Stefanos
    Athens - GREECE
    Tel: +30 210 6219520
    E-mail: info@virbac.gr
    Polska
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    España
    VIRBAC ESPAÑA S.A.
    ES-8950 Esplugues de Llobregat (Barcelona).
    Tél. : + 34 93 470 79 40
    Portugal
    VIRBAC DE Portugal
    LABORATÓRIOS LDA
    P-2080 Almeirim
    Tel: (351) 243 570 500
    France
    VIRBAC
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    E-mail: dar@virbac.fr
    România
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Ireland
    C&M Veterinary Distributors Limited
    IE-Limerick
    Tel: 353 61 314 933
    Slovenija
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    18
    Deutschland
    VIRBAC Tierarzneimittel GmbH
    West Rögen 20
    D-23843 Bad Oldesloe
    Tel: 49 (4531) 805 555
    Norge
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Ísland
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Slovenská republika
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Italia
    VIRBAC SRL
    Via dei Gracchi 30
    I-20146 Milano
    Tel: 39 02 48 53 541
    Suomi/Finland
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Κύπρος
    GEO. PAVLIDES & ARAOUZOS LTD
    25-27 Dimostheni Severi, 1080
    CY-1080 Nicosia - CYPRUS
    Τηλ: + 357 22456117
    E-mail: theodosiou.vet@gpa.com.cy
    Sverige
    VIRBAC S.A.
    1 ère avenue 2065 m – L.I.D
    F-06516 Carros
    Tel: 33 (0) 4 92 08 73 00
    Latvija
    OÜ ZOOVETVARU
    Pärnasalu 31
    ET - 76505 Saue/Harjumaa, ESTONIA
    Tel: + 372 6 709 006
    E-mail: margus@zoovet.ee
    United Kingdom
    VIRBAC Ltd
    UK-Suffolk IP30 9 UP
    Tel: 44 (0) 1359 243243
    Lietuva
    OÜ ZOOVETVARU
    Pärnasalu 31
    ET - 76505 Saue/Harjumaa, ESTONIA
    Tel: + 372 6 709 006
    E-mail: margus@zoovet.ee
    19


    Source: European Medicines Agency


    - Please bookmark this page (add it to your favorites).
    - If you wish to link to this page, you can do so by referring to the URL address below this line.

    https://theodora.com/drugs/eu/leucogen_veterinary.html

    Copyright © 1995-2021 ITA all rights reserved.